Pfizer Inc and GSK are close to bringing the first two vaccines for RSV to the United States after gaining the backing of a panel of advisers to the FDA.
The deal gives Moderna access to Generation Bio’s proprietary drug delivery system and DNA technology to develop drugs targeting immune cells and the liver.
Moderna Inc’s chief executive defended the company’s plan to quadruple the price of its COVID-19 vaccine, telling a U.S. Senate committee hearing it will no longer have the economies of scale from government procurement when the shots move into the private market.
The company expects to price its COVID-19 vaccine at around $130 per dose in the U.S. going forward as purchases move to the private sector from the government, the company’s president Stephen Hoge said in an interview.
Executives at three vaccine manufacturers – GSK, Moderna, and CSL Seqirus told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.
Moderna may seek the FDA’s accelerated approval for its personalized cancer vaccine, president Stephen Hoge said.
The sales forecast implies a “possible EPS net loss” this year compared to the huge profit its COVID vaccines drove during its peak.
The company announced its experimental personalized mRNA skin cancer vaccine in combination with Merck & Co Inc.’s drug Keytruda has received breakthrough therapy designation from U.S. regulators as an additional treatment for high risk patients.
Moderna Inc. will collaborate with privately owned Life Edit Therapeutics Inc. under an agreement to discover and develop mRNA gene-editing therapies, the companies said on Wednesday.
The race for an influenza vaccine is heating up as Moderna announced mixed interim results for its seasonal flu vaccine candidate Thursday.